Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr8.30 - kr38.33
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr211.16M
Enterprise Valuekr13.13M
Total Cash (Recent Filing)kr93.56M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)1.1
Beta1.41
Next Earnings
May 05, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)1.00
P/FCF Ratio-1.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces financial risk and interest burden, increasing flexibility to fund development or partner programs without near-term refinancing. This stronger capital structure supports durable operations and deal-making while management works to restore operating profitability.
High Gross Margin / Net Income SwingSustained ~70% gross margin suggests favorable unit economics for biologics production and potential for high profitability if operating costs are controlled. The TTM net income swing indicates upside potential, though converting this to recurring operating profit is required for durable earnings quality.
Partnership-driven, Capital-efficient Business ModelA partnership/out-licensing model shifts commercialization risk to partners and generates milestone, royalty and service revenues without full commercialization capex. Combined with in-house biologics development and manufacturing capabilities, this enables capital-efficient scaling and recurring partner-driven cash inflows.
Bears Say
Declining Revenue TrendA significant revenue decline erodes the base for operational leverage and questions demand or cadence of partnership milestones. Over months this reduces margin expansion potential, increases reliance on sporadic milestone income, and heightens execution risk for turning pipeline investments into stable sales.
Persistent Negative Cash Flow / Cash BurnConsistent negative operating and free cash flow creates ongoing financing need and raises dilution or refinancing risk. Over a multi-month horizon this constrains the firm's ability to fund R&D, manufacturing scale-up and regulatory work organically, making partnership timing critical to sustain operations.
Core Operations Still Loss-making; Earnings Quality WeakNegative operating profit and EBITDA indicate underlying business economics haven't yet converted to sustainable profitability. Reliance on non-operating gains or one-offs for reported net income raises earnings-quality concerns and implies the company must materially improve recurring revenues or margins to sustain results.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr8.30 and its highest was kr38.33 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr211.16M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 05, 2026 which is in 72 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2026. The company reported -kr1.29 earnings per share for the quarter, beating the consensus estimate of -kr1.49 by kr0.2.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.52.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr1.29 in its last earnings report, beating expectations of -kr1.49. Following the earnings report the stock price went down -13.017%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―